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MonophosphorylationERK1 and ERK2 (ERK1/2) are central to the regulation of cell division, growth and survival. They are activated
by phosphorylation of the Thr- and the Tyr- residues in their Thr-Glu-Tyr activation loops. The dogma is that
dually-phosphorylated ERK1/2 constitute the principal activities in intact cells. We previously showed that, in
neonatal rat cardiac myocytes, endothelin-1 and phorbol 12-myristate 13-acetate (PMA) powerfully and
rapidly (maximal at ~5 min) activate ERK1/2. Here, we show that dually-phosphorylated ERK1/2 rapidly
(b2 min) appear in the nucleus following stimulation with endothelin-1. We characterized the active ERK1/2
species in myocytes exposed to endothelin-1 or PMA using MonoQ FPLC. Unexpectedly, two peaks of ERK1
and two peaks of ERK2 activity were resolved using in vitro kinase assays. One of each of these represented the
dually-phosphorylated species. The other two represented activities for ERK1 or ERK2 which were
phosphorylated solely on the Thr- residue. Monophosphothreonyl ERK1/2 represented maximally ~30% of
total ERK1/2 activity after stimulation with endothelin-1 or PMA, and their kcat values were estimated to be
minimally ~30% of the dually-phosphorylated species. Appearance of monophosphothreonyl ERK1/2 was
rapid but delayed in comparison with dually-phosphorylated ERK1/2. Of 10 agonists studied, endothelin-1
and PMA were most effective in terms of ERK1/2 activation and in stimulating the appearance of
monophosphothreonyl and dually-phosphorylated ERK1/2. Thus, enzymically active monophosphothreonyl
ERK1/2 are formed endogenously following activation of the ERK1/2 cascade and we suggest that
monophosphothreonyl ERK1/2 arise by protein tyrosine phosphatase-mediated dephosphorylation of
dually-phosphorylated ERK1/2.ndothelin-1; FPLC, fast protein
K, MAPK kinase; PMA, phorbol
e; SDS-PAGE, sodium dodecyl
nd Metabolic Research, School
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The related prototypic MAPKs, ERK1 and ERK2 (ERK1/2), are
Pro-directed Ser-/Thr- protein kinases which regulate cell growth,
division and survival through their effects on gene expression and
other cellular processes [1–3]. In many dividing cells (including cell
lines), growth factor-binding to receptor protein Tyr- kinases leads to
activation of ERK1/2 [4,5]. This is also the case in primary cultures of(terminally-differentiated) neonatal rat cardiac myocytes [6,7] but
here robust ERK1/2 activation is also induced by Gq protein-coupled
receptor-/PKC-dependent pathways [8]. Thus, ligands such as
endothelin-1 (ET-1) and tumour-promoting phorbol esters (such as
phorbol 12-myristate 13-acetate, PMA) essentially stoicheiometri-
cally activate ERK1/2 in these cells [7].
ERK1/2 are the ﬁnal components of a protein kinase signalling
cascade in whichmembers of the Raf MAPK kinase kinase family (Raf-
1, A-Raf and B-Raf) phosphorylate and activate MAPK kinase kinases 1
and 2 (MKK1/2), which in turn phosphorylate and activate ERK1/2 [1].
In all 'classical' MAPKs (ERK1/2, JNKs and p38-MAPKα/β) and some
'novel' MAPKs, activation involves the phosphorylation of a Tyr-
residue and a Thr- residue in the activation loop Thr-Xaa-Tyr
sequence (Thr-Glu-Tyr in ERK1/2) to produce the dually-phosphor-
ylated MAPK species [1]. In mouse or rat, the relevant residues are
Thr-203 and Tyr-205 in ERK1, and Thr-183 and Tyr-185 in ERK2. The
general belief is that phosphorylation of both Tyr- and Thr- is
necessary for activation of ERK1/2.
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PMA have been separated into two discrete peaks of activity by MonoQ
Fast Protein Liquid Chromatography (FPLC) with ERK2 eluting at a lower
NaCl concentration [6,9]. We show here that each of these peaks of
ERK1orERK2activity canbe resolved further into twoseparatepeaks.One
of these two resolved peaks of ERK1 or ERK2 is dually-phosphorylated
[(pT-E-pY)ERK1/2], whereas the second peak is ERK1 or ERK2monopho-
sphosphorylated on the Thr- residue [(pT-E-Y)ERK1/2]. The important
conclusion is that monophosphothreonyl-ERK1/2 can be formed endog-
enously in cells and contribute signiﬁcantly to overall ERK1/2 activity.
2. Materials and methods
2.1. Antibodies
The antibody against total ERK1/2 was a rabbit polyclonal from Cell
Signaling Technology Inc. (cat. no. 9102). (pT-E-pY)ERK1/2 were
detected with a Sigma-Aldrich UK mouse monoclonal antibody (cat.
no. M9692) or a Cell Signaling Technology Inc. rabbit monoclonal
antibody (cat. no. 4377), as speciﬁed in the ﬁgure legends. The mouse
monoclonal antibodies against (pT-E-Y)ERK1/2 (cat. no. M3557, ERK-
YNP, clone 155 in Ref. [10]) and (T-E-pY)ERK1/2 (cat. no. M3682, clone
193 in Ref. [10]) were from Sigma-Aldrich UK. The rabbit anti-FLAG®
antibody was from Santa Cruz Biotechnology Inc. (cat. no. sc-7787).
Horseradish peroxidase-conjugated secondary antibodies to mouse
immunoglobulins (cat. no. P0260) and to rabbit immunoglobulins (cat.
no. P0448) were from Dako. The Alexa Fluor®488-conjugated second-
ary antibody to mouse immunoglogulins (cat. no. A11001) and Texas
Red-phalloidin (cat. no. T7471) were from Invitrogen.
2.2. Cardiac myocyte isolation and culture
Primary cultures of ventricular cardiacmyocyteswere prepared from
1- to 2-day-old Sprague–Dawley rats by an adaptation of the method of
Iwaki et al. [11] as described elsewhere [12]. Hearts were removed,
ventricles were dissected away from atria, and ventricular myocytes
were dissociated by serial digestion with 0.4 mg/ml collagenase and
0.6 mg/ml pancreatin in sterile digestion buffer (116 mM NaCl, 20 mM
HEPES, 0.8 mM Na2HPO4, 5.6 mM glucose, 5.4 mM KCl and 0.8 mM
MgSO4, pH 7.35). The ﬁrst digestion supernatant (5 min, 37 °C,
160 cycles/min in a shaking water bath) was removed and discarded.
Cell suspensions from subsequent digestions (20 min, 2×25 min,
20 min, 10 min; 37 °C, 136 cycles/min shaking) were recovered by
centrifugation (5 min, 60×g) and the cell pellets resuspended in plating
medium [Dulbecco's modiﬁed Eagle's medium/medium 199 (4:1 v/v),
15% (v/v) foetal calf serum, 100 units/ml of both penicillin and
streptomycin]. The cells were pre-plated on plastic Primaria tissue
culture dishes (30 min). The non-cardiomyocytes adhere to the dishes
whereas the cardiac myocytes remain unattached. For biochemistry
experiments, the non-adherent viable cardiac myocytes from the
pre-plates were plated at a density of 4×106cells/dish on 60 mm
Primaria dishes pre-coated at room temperature with sterile 1% (w/v)
gelatin (Sigma-Aldrich UK). For immunostaining experiments, cardiac
myocytes were plated at 2×106cells/dish on 35 mm Primaria dishes
containing glass coverslips pre-coated with gelatin as above followed by
laminin (Sigma-Aldrich UK, 20 μg/ml in PBS). After 18 h, myocytes were
conﬂuent and beating spontaneously. Unless they were to be infected
with adenovirus (AdV), serum was then withdrawn and myocytes
were incubated in maintenance medium [Dulbecco's modiﬁed Eagle's
medium/medium 199 (4:1 (v/v), 100 units/ml of both penicillin and
streptomycin] for a further 24 h.
2.3. Immunoﬂuorescence microscopy
Cardiac myocytes were exposed to ET-1 (100 nM), then washed 3×
with PBS and ﬁxed in 4% (v/v) formaldehyde (10 min, roomtemperature). Following permeabilisation with 0.1% (v/v) Triton
X-100 (10 min, room temperature), non-speciﬁc binding was blocked
with 2.5% (w/v) bovine serum albumin in 0.1% (v/v) Triton X-100
(10 min, room temperature). Antibodies and ﬂuorophoreswere diluted
in PBS, all incubations were at 37 °C, and coverslips were washed three
times in PBS after each stage of the immunostaining procedure.
Myocytes were stained with mouse primary monoclonal antibodies to
(pT-E-pY)ERKs (Sigma M9692) (1:80, 60 min) and Alexa Fluor®488-
conjugated secondary antibodies (1:200, 60 min). Myoﬁlamentous
actin was counterstained with Texas Red-phalloidin (5 U/ml, 20 min)
andnucleiwere counterstainedwithHoechst 33258 (10 μg/ml, 15 min).
Fluorescencemicroscopywas performed using a Zeiss Axio Observer Z1
inverted microscope equipped with a Zeiss LSM710 confocal imaging
system, and using a Plan-Apochromat 63×/1.4 oil-immersion objective.
Standard excitation and emission presets were chosen for Hoechst
33258, Alexa 488, and Texas Red dyes, whichwere imaged sequentially
to eliminate ﬂuorescence bleed-through. All ﬁelds were captured at a
resolution of 512×512 pixels using a zoom factor of 1.2× with a ﬁeld
dimension of 112×112 μm.2.4. AdV vector for FLAG-ERK2
The AdV-FLAG-ERK2 vector was prepared using the AdEasy™ XL
Adenoviral Vector System (Stratagene) using the general methodology
described previously [13]. The FLAG sequence (placed 3′ to an initiation
codon) was introduced into the pShuttle-CMV vector and the mouse
ERK2 coding sequence was placed in frame and 3′ to the FLAG tag. The
FLAG sequence was ﬁrst introduced between the BglII and KpnI
restriction sites in the multiple cloning site of the pShuttle-CMV vector
by synthesis of an oligonucleotide cassette containing the FLAG
sequence preceded by an ATG start codon. The complementary
oligonucleotides used were:
Forward 5′-GATCTACCATGGACTACAAAGACGATGACGACAAGGGTA
CCGTCGACGC-3′;
Reverse 5′-GGCCGCGTCGACGGTACCCTTGTCGTCATCGTCTTTGTAGTCC
ATGGTA-3′
with the FLAG sequence underlined and emboldened, and its
antisense complement underlined and italicized. The oligonucleotides
were annealed and phosphorylated, resulting in a cassette ﬂanked by
'cut' BglII and NotI sites, which was then inserted into the
corresponding restriction sites in the multiple cloning site of
pShuttle-CMV. This strategy, which replaces the KpnI–NotI fragment
of pShuttle-CMVwith an identical sequence in the cassette insert, was
used to avoid the potential difﬁculty of cutting both the BglII and KpnI
sites which lie immediately adjacent to each other in pShuttle-CMV.
The mouse ERK2 coding sequence was ampliﬁed from a glutathione-
S-transferase-ERK2 fusion construct in pGEX4T-1 (gift of Professor
Chris Marshall, Institute of Cancer Research, London) with Pfu
polymerase using forward primer: (5′-GACGACAAGGGTAC-
CATGGCGGCCGCAGCAGCGGCCGGC-3′) and reverse primer (5′-
CTTATCTAGAAGCTTTTAAGATCTGTATCCTGGCTGGAATCTAGCAG-3′)
to produce ERK2 ﬂanked by KpnI and HindIII sites (underlined and
emboldened) which were then used for insertion into the
corresponding sites in FLAG-pShuttle-CMV, 3′ and in frame with the
FLAG sequence. All constructs were sequenced on an ABI3730xl or
ABI3130xl automated ﬂuorescent DNA sequencer at the Clinical
Sciences Centre Genomics Core Laboratory (Imperial College London).
Shuttle plasmids containing veriﬁed sequences were then linearised
with PmeI and used to transform BJ5183-AD-1 cells which were
subsequently screened for homologous recombination. AdV plasmids
from positive recombinants were expanded in XL10Gold cells,
linearised with PacI and used to transform HEK293 cells, as described
in the AdEasy XL Adenoviral Vector System manual. Viruses were
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withdrawn from cardiac myocytes 6 h before AdV.FLAG-ERK2 infections.
The multiplicity of infection was titrated to give about 10-fold greater
expression of FLAG-ERK2 over endogenous ERK2 at 20 h after infection.
2.5. MonoQ FPLC
After the various treatments, cardiacmyocyteswerewashed 3×with
ice-cold PBS, scraped into 150 μl Buffer A [20 mM β-glycerophosphate
(pH 7.5), 50 mM NaF, 2 mM EDTA, 0.004 mM microcystin LR, 1% (v/v)
Triton X-100, 5 mM dithiothreitol, 10 mM benzamidine, 0.2 mM
leupeptin, 0.01 mM trans-epoxy succinyl-l-leucylamido-(4-guanidino)
butane, 0.3 mM phenylmethylsulphonyl ﬂuoride], and extracts were
clariﬁedby centrifugation (10,000×g, 5 min, 4 °C). Extracts from4dishes
of uninfected cardiac myocytes or from 2 dishes of AdV.FLAG-ERK2
infected myocytes were loaded onto a MonoQ HR 5/5 FPLC column and
ERK1/2 activities were separated using an Äkta™ FPLC system (GE
Healthcare). The columnwas equilibratedwith Buffer B (50 mMTris/HCl
pH 7.3, 2 mMEDTA, 2 mMEGTA, 0.1% (v/v) 2-mercaptoethanol, 5% (v/v)
glycerol, 0.03% (v/v) Brij-35, 0.3 mM Na3VO4, 1 mM benzamidine and
4 μg/ml leupeptin). Following a 5 ml isocratic wash, discontinuous linear
NaCl gradients were formed by mixing Buffer B with Buffer C (Buffer B
containing 1 M NaCl) as described in the ﬁgure legends.
2.6. Western blotting
MonoQ FPLC fractions or whole cell supernatant extracts were
denatured by heating at 100 °Cwith 0.33 vol. sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer [300 mM
Tris–HCl pH 6.8, 10% SDS (w/v), 13% glycerol (v/v), 130 mM
dithiothreitol, 0.2% bromophenol blue (w/v)]. Proteins (25 μl in sample
buffer) were separated by SDS-PAGE [10% (w/v) resolving gels with 6%
(w/v) stacking gel] and transferred electrophoretically to nitrocellulose.
Non-speciﬁc binding sites were blocked with 5% (w/v) nonfat milk
powder in TBSTbuffer [20 mMTris–HCl pH7.5, 137 mMNaCl, 0.1% (v/v)
Tween 20] for 30 min. Blots were incubated with primary antibodies in
TBST buffer containing 5% (w/v) bovine serum albumin overnight at
4 °C. Antibody dilutions were: total ERK1/2, 1/1000; pT-E-pY(ERK2)
(Cell Signaling Technology antibody), 1/1000; (pT-E-pY)ERK1/2
(Sigma-Aldrich UK antibody), 1/30,000; (pT-E-Y)ERK1/2, 1/10,000;
(T-E-pY)ERK1/2, 1/4000; FLAG, 1/10,000. The blots were washed with
TBST buffer (3×5 min, room temperature), incubated with secondary
antibodies (1:5000 dilution in TBST buffer containing 1% (w/v) nonfat
milk powder, 1 h, room temperature) and then washed again in TBST
buffer (3×5 min, room temperature). Bands were detected by
enhanced chemiluminescence (Santa Cruz Biotechnology) using
Hyperﬁlm MP and were quantiﬁed by scanning densitometry.
2.7. Measurement of ERK1/2 activities
ERK1/2 activities in FPLC fractions (40 μl sampled) were measured
by incorporation of 32P from 0.1 mM [γ-32P]ATP (0.5 μCi per assay) into
myelin basic protein (MBP, Upstate, 15 μg per assay) in the presence of
20 mM MgCl2/2 μM protein kinase A inhibitor (Calbiochem). Assays
(50 μl ﬁnal volume) were initiated with 5 μl of 1 mM [γ-32P]ATP/
200 mM MgCl2, incubated at 30 °C for 30 min, and terminated by
sampling (40 μl) onto P81 paper squares which were then washed in
75 mM H3PO4 (4×15min) on a rocking platform. Radioactivity was
measured by Čerenkov radiation counting.
In some cases, ERK1/2 activities were examined by 'in-gel' MBP
kinase assays. Fractions from FPLC were denatured with SDS-PAGE
sample buffer and subjected to SDS-PAGE in 10% polyacrylamide gels
containing 0.5 mg/ml MBP incorporated covalently into the gel
matrix. After electrophoresis, SDS was removed from the gel by
washing (3×20 min) with 20% (v/v) 2-propanol in 50 mM Tris/HCl,
pH 8.0, then in 5 mM 2-mercaptoethanol in 50 mM Tris/HC1, pH 8.0(3×20 min). Proteinswere further denatured bywashing thegel in 6 M
guanidine HCl in 50 mM Tris/HC1 pH 8.0/5 mM 2-mercaptoethanol
(2×20 min), then renatured by extensive washing in 50 mM Tris/HCl,
pH 8.0, containing 0.04% (v/v) Tween-40 and 5 mMmercaptoethanol at
4 °C. After pre-incubation of the gel at 20 °C for 1 h in 40 mM HEPES,
2 mM dithiothreitol, 10 mM MgCl2, pH 8.0, in situ phosphorylation of
MBP was performed in 40 mM HEPES, 0.5 mM EGTA, 10 mM MgCl2,
2 μM protein kinase A inhibitor, 0.1 mM [γ-32P]ATP, pH 8.0 (5 ml/gel,
containing 12.5 μCi [γ-32P]ATP) at room temperature for 3 h. After
extensive washing in 5% (w/v) trichloroacetic acid/1% (w/v) sodium
pyrophosphate, gels were dried and autoradiographed.
2.8. Data interpretation
Graphs were constructed using GraphPad Prism 4.0 software and
results are presented as means±S.E.M. Areas under the curves were
calculated using Origin Pro 8 software.
3. Results
3.1. Immunoﬂuorescence microscopy
Immunoﬂuorescence microscopy showed that (pT-E-pY)ERK1/2
appeared transiently in cardiac myocytes exposed to 100 nM ET-1
(Fig. 1). At zero time, some background staining of (pT-E-pY)ERK1/2
was detectable (Fig. 1). By 2 min, staining had increased dramatically
in the nucleus and, to a lesser extent, in the cytoplasm. After 5 min,
staining was maximal in both compartments but, by 10 min, staining
was declining in both. This transience is consistent with enzyme
activity measurements [6].
3.2. MonoQ FPLC of extracts of cardiac myocytes exposed to ET-1 or PMA
By reducing the ﬂow rate and using a shallow NaCl gradient, we
separated ﬁve peaks of MBP kinase activity (peak A and peaks I–IV) in
extracts of cardiacmyocytes exposed for 5 min to 100 nMET-1 (Fig. 2A)
or 1 μM PMA (Fig. 2B), conditions that maximally activate ERK1/2 in
these cells [7,9]. Activities in Peaks I–IVwith ET-1 or PMAwere about 6-
fold greater than in the controls. PD184352 is an allosteric inhibitor of
MKK1/2 [14]. Exposure of cardiac myocytes to PD184352 (2 μM,
15min) reduced MBP kinase activities to below control values and
prevented subsequent activation of MBP kinase peaks I–IV by ET-1
(Fig. 2C). These results, together with previous ﬁndings [6,9], suggest
that the MBP kinase activities in Peaks I–IV represent either ERK1 and
ERK2 themselves, or that one or more of the activities represents
downstream effector protein kinases activated by ERK1/2.
The MonoQ fractions in Fig. 2A,B, were immunoblotted for total
(i.e. phosphorylated + non-phosphorylated) ERK1/2 (Fig. 2D). In
extracts from control cells, 42 kDa ERK2 eluted over fractions 16-22
(maximal in fractions 18–19) and 44 kDa ERK1 eluted over fractions
24–29 (maximal in fractions 26–27) (Fig. 2D). In extracts of cells
exposed to ET-1 or PMA, ERK1 and ERK2 eluted at slightly higher NaCl
concentrations because of the negative charges introduced by
phosphorylation. MBP kinases (Fig. 2A,B) in Peak I (peak fractions
19–20 eluting at ~0.14 M NaCl) and Peak II (peak fractions 23–24
eluting at ~0.16 M NaCl) contained ERK2 (Fig. 2D). Peak III (peak
fractions 29–30 eluting at ~0.17 MNaCl, and overlappingwith Peak II)
contained ERK1 as did Peak IV (peak fractions 40–41 eluting at
~0.20 M NaCl) (Fig. 2A,B,D).
Selected fractions were immunoblotted with antibodies recognis-
ing various phosphorylated forms of ERK1/2. In extracts of myocytes
exposed to ET-1 or PMA, antibodies recognising (pT-E-pY)ERK1/2
showed that Peak II (fractions 23 and 25) contained (pT-E-pY)ERK2
and Peak IV (fraction 41) contained (pT-E-pY)ERK1 (Fig. 2E).
Monoclonal antibodies selective for (pT-E-Y)ERK1/2 [10] showed
that Peak I (fractions 18 and 20) contained (pT-E-Y)ERK2 and Peak III
Fig. 1. Immunoﬂuorescence microscopy of (pT-E-pY) ERK1/2 in cardiac myocytes exposed to endothelin-1 (ET-1). Following exposure to ET-1 (100 nM) for the times indicated,
myocytes were stained for nuclei (blue), (pT-E-pY)ERK1/2 (green, Sigma-Aldrich antibody), or actin ﬁlaments (red). The combined overlay images are also shown. Representative
ﬁelds (out of 3) from an individual experiment are shown and the experiment was repeated 3 times on separate preparations of myocytes. Scale bar=50 μm.
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ERK1/2-selective antibody [10] did not detect any signiﬁcant
immunoreactivity in Peaks I–IV, though it may have detected some
immunoreactivity in Peak A (fraction 7) (Fig. 2E). We cannot
deﬁnitely exclude the possibility that there is some formation of
(T-E-pY)ERK1/2 because the antibody may simply be unable to detect
it, but we were unable to detect any signal using a variety of dilutions.
Our interpretation of these experiments is that, in addition to (pT-E-pY)
ERK1/2, (pT-E-Y)ERK1/2 can be readily detected in cardiac myocytes
exposed to ET-1 or PMA in intact cells and these species are enzymically
active.
In addition to ERK1/2, a 46 kDa 'ERK' protein was detected in
fractions6–7 andwhich corresponded to theMBPkinase activity in Peak
A eluting at ~0.11 M NaCl (Fig. 2A,B). This may be ERK1b, identiﬁed
previously in Rat1 cells, which is expressed in highest abundance inheart [15]. ERK1b is an alternatively-spliced 406 residue protein
containing a 26-residue insert between residues 340 and 341 in rat
ERK1 [15]. In comparison with peaks I–IV, Peak A MBP kinase was
relatively poorly activated (~2-fold) by ET-1 (Fig. 2A) or PMA (Fig. 2B).
We also performed 'in-gel' MBP kinase assays [7] on selected
fractions. Such assays require the renaturation of denatured phos-
phorylated ERK1/2. Interestingly, only the dually-phosphorylated
forms (fractions 21, 22, 38 and 39) of ERK1 (migrating at 44 kDa) and
ERK2 (migrating at 42 kDa) were able to renature (Fig. 2F) and
phosphorylate MBP.
3.3. Relative contributions and speciﬁc activities of phospho-ERK1/2 species
Integration of the curves in Fig. 2A,B, showed that the enzymic
activity attributable to (pT-E-Y)ERK1/2 is considerable and represents
Fig. 2.MonoQ FPLC of ERK1/2 in extracts of cardiac myocytes. Myocytes were exposed to 100 nM ET-1 for 5 min, 1 μM PMA for 5 min, or to 2 μM PD184352 for 15 min followed by
100 nM ET-1 for 5 min, and extracts were applied to MonoQ columns. Following a 5 ml isocratic wash, the NaCl concentration was increased in a stepwise fashion to 0.1 M (2 ml).
ERK1/2 activities were eluted with a linear NaCl gradient (0.1 M–0.22 MNaCl, 12 ml). Flow rate was 0.5 ml/min, 0.25 ml fractions were collected andMBP kinase activities measured.
When shown, the broken line denotes the NaCl concentration. For the MonoQ FPLC proﬁles (A–C): ▲, control (A–C); ●, ET-1 (A,C) or PMA (B); ■, PD184352 pre-exposure followed
by ET-1 (C). Experiments where responses to both ET-1 and PMAwere examined separately but contemporaneously (A and B) were repeated on 4 different preparations of myocytes
with similar results. For the effects of PD184352 (C), the experiment was repeated once with similar results. D, E. Immunoblotting of MonoQ FPLC fractions from (A) and (B). D, total
(i.e. phosphorylated + non-phosphorylated) ERK1/2 was immunoblotted across the MonoQ FPLC fractions. E. Selected fractions of peak MBP kinase activity following MonoQ FPLC
separations from (A) and (B)were immunoblotted for (pT-E-pY)ERK1/2 (Cell Signaling Technology Inc. antibody), (pT-E-Y)ERK1/2, (T-E-pY)ERK1/2 or total ERK1/2. F, 'in-gel'MBP kinase
assays. Selected fractions containingpeakMBPkinase activity followingMonoQFPLC ofmyocytes exposed to 100 nMET-1 for 5 min from(A)were examinedby 'in-gel'MBP kinase assays.
The experiment was repeated once with similar results.
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100 nM ET-1 (9 separate preparations of cardiac myocytes) or 1 μM
PMA for 5 min (5 separate preparations of myocytes).
Approximate relative speciﬁc activities (turnover numbers or kcat) of
(pT-E-Y)ERK1/2 and (pT-E-pY)ERK1/2 were estimated from data in
Fig. 2A,B,E on the followingbasis. In extracts of control cardiacmyocytes,
antibodies against total ERK1/2 or any of the phospho-ERK1/2 species
did not detect signiﬁcant immunoreactivity in fractions 23 and 41. On
activation of ERK1/2 by ET-1 or PMA, immunoreactivity became
detectable with antibodies against total ERK1/2 or (pT-E-pY)ERK1/2,
but not (pT-E-Y)ERK1/2, in fractions 23 (ERK2) and 41 (ERK1). Thus,
essentially all enzymic activity and total immunoreactivity in these
fractions was attributable to (pT-E-pY)ERK1/2. The ratio of measured
enzymic activity to total ERK1/2 in fractions 23 and 41 thus provided a
measure of the speciﬁc activity for (pT-E-pY)ERK1/2.
For fractions 20 and 30, antibodies against total ERK1/2 detected
immunoreactivity but negligible enzymic activity in control incubations
of cardiac myocytes. However, both immunoreactivity and signiﬁcant
enzymic activity were detected in cardiac myocytes exposed to ET-1 or
PMA but (pT-E-Y)ERK1/2 were the only phosphorylated species
detectable. The ratio of measured enzymic activity to total ERK1/2 in
fractions 20 and 30 thus provided a minimum measure of the speciﬁc
activity for (pT-E-Y)ERK1/2 because the contribution of inactive ERK1/2
to the denominator cannot be assessed. From the data shown, the
minimum speciﬁc activities (mean±S.E., n=5) of (pT-E-Y)ERK1 andFig. 3.MonoQ FPLC of ERK1/2 in extracts of AdV.FLAG-ERK2-infected cardiac myocytes
following exposure to ET-1. Myocytes were uninfected, or were infected with AdV.
FLAG-ERK2 and exposed to 100 nM ET-1 for 5 min as required. A, ERK1/2 activities were
separated by MonoQ FPLC (see legend of Fig. 1), except that ﬂow rate and fraction size
were reduced to 0.25 ml/min and 0.15 ml, respectively, and MBP kinase activities
measured. Control values (no infection or exposure to ET-1) were essentially at baseline
values on this scale. ▲, myocytes infected with AdV.FLAG-ERK2, no ET-1 exposure;
● myocytes infected with AdV.FLAG-ERK2 and exposed to ET-1; ■, uninfected
myocytes exposed to ET-1. The broken line denotes the NaCl concentration. B, fractions
48 and 54 (5 μl/lane) were immunoblotted. For (pT-E-pY)ERK2 detection, the Sigma-
Aldrich antibody was used. The experiment was repeated with similar results.(pT-E-Y)ERK2 were calculated to be 29±1% and 30±2% of those of
(pT-E-pY)ERK1 and (pT-E-pY)ERK2, respectively.3.4. Infection of cardiac myocytes with AdV.FLAG-ERK2
In order to ensure that activities in Peaks I and III (Fig. 2A,B)were not
MBP kinases activated downstream from ERK1/2, we infected cardiac
myocyteswithAdV.FLAG-ERK2. Infected anduninfectedmyocyteswere
exposed to 100 nM ET-1 (5 min) and MBP kinase activities measured
following MonoQ FPLC. The additional negative charge of the FLAG
epitope shifted the elution of FLAG-ERK2 activity to a position between
Peaks III and IV (Fig. 3A). Treatment of AdV.FLAG-ERK2-infected
myocytes with ET-1 resulted in a large increase in MBP kinase activityFig. 4. Phosphorylation of ERK1/2 in fresh extracts of cardiac myocytes exposed to ET-1.
Cardiac myocytes were exposed to 100 nM ET-1 for the times indicated, extracts were
prepared immediately andwere examined by immunoblotting with antibodies to (A, B)
total ERK1/2 (centre panels); A, antibodies to (pT-E-pY)ERK1/2 (Sigma-Aldrich
antibody) (upper panel), or B, (pT-E-Y)ERK1/2 (upper panel). A, B, The lower panels
show quantiﬁcation of immunoblots for A, (pT-E-pY)ERK1 or (pT-E-pY)ERK2, or B,
(pT-E-Y)ERK1 or (pT-E-pY)ERK2. ●, solid line, ERK1; ■, broken line, ERK2. Results are
means±S.E.M. for 4 different preparations of myocytes.
474 P.H. Sugden et al. / Cellular Signalling 23 (2011) 468–477in fractions 46–62 (note that fraction numbers in Fig. 3 are not
comparable to those in Fig. 2 because fraction size was reduced).
Fractions 48 (minor peak of FLAG-ERK2 activity) and 54 (major peak of
FLAG-ERK2 activity) were characterised further (Fig. 3B). As expected,
total ERK2 or FLAG immunoreactivity was present in much greater
abundance in fractions 48 and 54 from AdV.FLAG-ERK2-infected
myocytes (control or ET-1-treated) than in uninfected myocytes
(Fig. 3B). (pT-E-pY)ERK1/2 were not detected in uninfected or AdV.
FLAG-ERK2-infected controlmyocytes, though therewas some (pT-E-Y)
ERK1/2 immunoreactivity detectable in fraction 48 of the AdV.FLAG-
ERK2-infected controls (Fig. 3B). We do not understand the reasons for
this. In AdV.FLAG-ERK2-infected myocytes exposed to ET-1, a strong
(pT-E-pY)ERK2 signal was detected in fraction 54 with a weaker signal
in fraction 48 (Fig. 3B). Conversely, (pT-E-Y)ERK2 was readily detected
in fraction 48 with a weaker signal in fraction 54 (Fig. 3B). These data
conﬁrm that all the MBP kinase activities in peaks I–IV (Fig. 2A,B) are
monophosphorylated or dually-phosphorylated ERK1 or ERK2, rather
than MBP kinases downstream from ERK1/2.
3.5. Time courses of ERK1/2 phosphorylation
Cardiac myocytes were exposed to 100 nM ET-1 for various times
and cell extracts were immunoblotted directly with (pT-E-pY)ERK1/2
(Fig. 4A) or (pT-E-Y)ERK1/2 antibodies (Fig. 4B). (pT-E-pY)ERK1/2were
detectable within 30 s and maximal at 1–2 min (Fig. 4A), whereas
(pT-E-Y)ERK1/2 were not detected before 1 min but were maximal
at ~5 min (Fig. 4B). These ﬁndings suggest (but do not prove) a
precursor–product relationship with (pT-E-Y)ERK1/2 resulting from
dephosphorylation of (pT-E-pY)ERK1/2. The time course of activation of
ERK1/2 by ET-1 was also examined by MonoQ FPLC (Fig. 5A). Areas
under individual peaks were integrated and plotted against time
(Fig. 5B). Peak II [(pT-E-pY)ERK2] and Peak IV [(pT-E-pY)ERK2] were
detectable within 30 s, rose to a maximum at 1 – 2 min, then gradually
declined over the subsequent 40 min (Fig. 5A,B). Peak I [(pT-E-Y)ERK2]
and Peak III [(pT-E-Y)ERK1] were not detected until 1 min, then
increased to amaximumat2–5 min (Peak I) or 1–2 min (Peak III) before
declining subsequently. These ﬁndings were conﬁrmed by immuno-
blotting fractions containing the highest activities of Peaks I–IV
(fractions 19, 23, 29 and 40, respectively) with antibodies against
(pT-E-pY)ERK1/2 and (pT-E-Y)ERK1/2 (Fig. 5C). As an aside, therewere
two bands of total ERK2 in the 0.5–2 min samples of fraction 19 [which
contains only (T-E-Y)ERK2 and (pT-E-Y)ERK2]. The more slowly
migrating band is presumably (pT-E-Y)ERK2. Migration of ERK2 is
reduced by phosphorylation and the result here showed that phos-
phorylation of the Thr- residue alonemay be adequate to cause the shift.
3.6. Comparison of agonist efﬁcacy in (pT-E-Y)ERK1/2 and (pT-E-pY)
ERK1/2 formation in cardiac myocytes
Numerous agonists stimulate ERK1/2 activities and phosphorylation
in cardiac myocytes [6–9,16–21]. We compared the MonoQ FPLC activityFig. 5. Time courses of activation and phosphorylation of ERK1/2 by ET-1 in extracts of
cardiac myocytes examined byMonoQ FPLC. Experiments were carried out as described
in the Legend to Fig. 2 with the exception that the length of exposure of myocytes to
100 nM ET-1 was varied. A, MonoQ FPLC. MBP kinase activities were expressed as a
percentage of total MBP kinase activity following the standard exposure of myocytes to
(maximally-activating) 100 nM ET-1 for 5 min. Elution proﬁles are offset to prevent
overlapping, but the baseline values are identical all each cases. Results are
representative of 3 different preparations of myocytes. B, MBP kinase activities in
peaks I–IV (as deﬁned in Fig. 1). Activities in the individual peaks I–IV from MonoQ
FPLC were calculated by curve ﬁtting and are shown as means±S.E.M. for 3
independent observations on separate preparations of myocytes. ●, solid line, Peak I
(pT-E-Y)ERK2; ○, solid line, Peak II (pT-E-pY)ERK2; ■, broken line, Peak III (pT-E-Y)
ERK1;□, broken line, Peak IV (pT-E-pY)ERK1. C, fractions 19, 23, 29 and 40 (peaks I–IV,
respectively, Fig. 5A) were immunoblotted with antibodies against (pT-E-pY)ERK1/2
(top panels), (pT-E-Y)ERK1/2 (centre panels), or total ERK1/2 (bottom panels). Results
are representative of 3 different preparations of myocytes.proﬁles for 10 agonists (Fig. 6A) and derived the relative contribution of
eachpeakof activity to the total activity (i.e. the sumof activities in all four
peaks) using activation by ET-1 (100 nM, 5 min) as an internal standard
and taking it as 100%. The time of sampling was when the response to
each agonist was maximal and maximally effective concentrations were
chosen. In terms of total activity, ET-1 and PMA caused the greatest
activation and H2O2 the least (Fig. 6A). Essentially the same spectrum
of activation was seen for Peak II [(pT-E-pY)ERK2, Fig. 6C] and Peak IV
[(pT-E-pY)ERK1, Fig. 6E], and plots of activities in these peaks against
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Fig. 6. Comparison of activation of ERK1 and ERK2 in cardiac myocytes by various agonists as determined by MonoQ FPLC. Myocytes were exposed to agonists at their maximally effective
concentrations and times, and ERK1/2 activities in the extractswere examinedusingMonoQFPLC. Agonist concentrations and lengths of exposurewere: ET-1, 100 nM for 5 min (n=8); PMA
1 μM for 5 min (n=5); bradykinin (BK) 10 μM for 5 min (n=3); EGF, 20 ng/ml for 5 min (n=3); PDGF, 20 ng/ml for 5 min (n=3); phenylephrine (PE), 100 μM for 5 min (n=5);
hyperosmotic shock (HOS)with0.5 Msorbitol (n=3) for30 min;H2O20.1 mMfor15 min (n=3); IL-1β, 10 ng/ml for 15 min (n=3); isoprenaline(ISO), 50 μMfor5 min(n=3).MBPkinase
activities in fractionsweremeasuredandpeaksof activitywere integrated. Inall cases, ET-1 standards (myocytes exposed to100 nMET-1 for 5 min)were included, and the total activity or the
activity ineachpeakwas expressedas apercentage relative to the total activity inducedbyET-1.A, total activity;B,Peak I activity [(pT-E-Y)ERK2];C, Peak II activity [(pT-E-pY)ERK2];D, Peak III
activity, [(pT-E-Y)ERK1]; E, Peak IV activity [(pT-E-pY)ERK1]. F, G, activities in Peak I, Fig. 6B [(pT-E-Y)ERK2 relative to the ET-1 total activity standard] and Peak III, Fig. 6D [(pT-E-Y)ERK1
relative to the ET-1 total activity standard] were plotted against total activity relative to the ET-1 standard (panel A) for each agonist. All results are means±S.E.M. F, points were ﬁtted to a
fourth-order polynomial non-linear regression equation (r2=0.98). G, points were ﬁtted to a linear regression. In both cases, the lines were forced through the origin.
475P.H. Sugden et al. / Cellular Signalling 23 (2011) 468–477total activity relative to ET-1 were linear (pb0.0001, data not shown).
However, for Peak I [(pT-E-Y)ERK2], there appeared to be a 'threshold'
effect with disproportionately large effects of ET-1 and PMA relative tototal activity (Fig. 6B,F). This contrasted with the other monopho-
sphorylated species in Peak III [(pT-E-Y)ERK1, Fig. 6D] where the
abundance of (pT-E-Y)ERK1 was proportional to the total ERK1/2
476 P.H. Sugden et al. / Cellular Signalling 23 (2011) 468–477activities (Fig. 6G). Thus the relative abundance of (pT-E-Y)ERK reﬂects
the abundance of total (pT-E-pY)ERK only in the case of ERK1.
4. Discussion
Classically, activation of ERK1/2 involves phosphorylation of the Thr-
andTyr- residues in the activation loopThr-Glu-Tyr by thedual-speciﬁcity
kinases MKK1/2 in an ordered, 'distributive' manner [1,22–26]. In
non-phosphorylated ERK2 (and presumably ERK1), the activation loop
Tyr- lies in a hydrophobic pocket with its –OH group buried, whilst the
Thr- is on the surface. First of all, Tyr-185 is phosphorylated by MKK1/2
causing a conformational change, with the phospho-Tyr- side chain
moving to the surface of the protein making four interactions with two
Arg- residues and thus presumably stabilising the (T-E-pY)ERK2
conformation of the enzyme. The MKK1/2 then dissociates and second
MKK1/2 binds to (T-E-pY)ERK2 and phosphorylates the Thr- residue,
thereby forming a further 8 ionic contacts. The Tyr- phosphorylation is
important in protein substrate recognition whereas the Thr- phosphor-
ylation improves the geometry of the active site. This model is supported
by demonstration of distinct structures for the non-phosphorylated, Tyr-
phosphorylated, and dually-phosphorylated forms of ERK1 [27]. The
ordered mechanism has led to the conclusion that phosphorylation of
bothThr- andTyr- residues is essential for full activityofERK1/2. It became
generally assumed that monophosphorylated forms are, at best, low kcat
species and, if they occur endogenously in cells in vivo, it is only in low
abundances. However, an alternative interpretation is that phosphoryla-
tionof theTyr- is anobligatory step for stabilisationof the ‘transition state’,
and that it precedes and is required for the Thr- phosphorylation.
However, once the activation loop Thr- is phosphorylated, the phosphate
of phospho-Tyr could be dispensable. This may explain why, although
(pT-E-pY)ERK1/2 activities renatured in ‘in-gel’ kinase assays (Fig. 2F),
(pT-E-Y)ERK1/2 activities did not because the Tyr-phosphorylation is
necessary for renaturation.
Many agonists activate ERK1/2 the ERK1/2 cascade in cardiac
myocytes to varying degrees (Fig. 6) with ET-1 and PMA being most
potent (as we have shown previously [7,9]). (pT-E-pY)ERK1/2
appeared rapidly (within 2 min) in both the nuclei and cytoplasm of
cardiac myocytes exposed to ET-1 before declining (Fig. 1), a similar
response to that seen with PMA [28]. Thus, (pT-E-pY)ERK1/2 are
correctly localised to regulate ET-1-mediated transcriptional events,
the majority of which are dependent on activation of the ERK1/2
cascade in cardiac myocytes [29,30]. However, we were unconvinced
that we could detect any production of (pT-E-Y)ERK1/2 by immu-
nostaining (results not shown) and suggest that this is simply a
problem with immunostaining with the (pT-E-Y)ERK1/2 antibody.
Here, we show that (pT-E-Y)ERK1/2 can be responsible for up to ~30%
of total ERK1/2 activity inmammalian cells (Fig. 2). Toour knowledge, this
is theﬁrst direct demonstration of signiﬁcant endogenous (pT-E-Y)ERK1/2
activity in vivo. The general assumption has been that (pT-E-Y)ERK1/2 or
(T-E-pY)ERK1/2 are essentially enzymically-inactive and that, if they do
occur in vivo, they only occur in low abundances. However, in vitro,
recombinant (pT-E-F)ERK2was about 7- to 8-foldmore active than (T-E-
F)ERK2, though the resulting activity was still b0.5% of that of (pT-E-pY)
ERK2 [26,31]. Similarly, (A-E-pY)ERK2 was about 100-fold more active
than (A-E-Y)ERK2 but this was only about 2% of the activity of (pT-E-pY)
ERK2. However, activation loop mutants of ERK2 was used in these
experiments and these may not be of strict relevance to (T-E-Y)ERK2.
Zhou and Zhang [32] generated (pT-E-Y)ERK2 and (T-E-pY)ERK2) in
vitro by treating recombinant (pT-E-pY)ERK2 with the protein Tyr-
phosphatase (PTP) PTPN7 (HePTP) or the protein Ser-/Thr- phosphatase
PP2Cuntil activitieshaddecreased toaminimumand(pT-E-pY)ERK2was
not detectable immunologically. The kcat values of (T-E-Y)ERK2, (pT-E-Y)
ERK2, (T-E-pY)ERK2 and (pT-E-pY)ERK2 were 1, 227, 620 and 8940 s−1,
respectively, with MBP as substrate with corresponding 'Km' values of
22.9. 15.5, 15.2, and 10.0 μM. A similar rank order was obtained with, the
transactivation domain of the Elk-1 transcription factor, a more'physiological' substrate. Our estimates of the relative speciﬁc activities
of (pT-E-Y)ERK1/2 to (pT-E-pY)ERK1/2of ~30%are somewhathigher that
the 7% of Zhou & Zhang [32].
Both (pT-E-Y)ERK1/2 and (T-E-pY)ERK1/2) have been detected by
immunoﬂuorescence or immunoblotting in intact ErbB1-overexpres-
sing CHO cells following short-term (up to 15 min) exposure to EGF
[10]. They were thought to arise from selective dephosphorylation of
(pT-E-pY)ERK1/2 by either PTPs or protein Ser-/Thr- phosphatases, but
were assumed to be enzymically-inactive. (pT-E-Y)ERK1/2 were
predominantly cytoplasmic and (T-E-pY)ERK1/2 were predominantly
nuclear. Additionally, (T-E-pY)ERK1/2 formed by the action of PP2A
phosphatase have been detected in the nuclei of cell lines but also co-
localised with the Golgi apparatus during the G2/M phase of the cell
cycle, when they may be involved in Golgi disassembly [33,34]. Their
role in the Golgi seemed to be dependent on the monophosphorylation
itself rather than ERK1/2 activity.
Other studies using a Tyr- to Phe mutation in the T-G-Y
phosphorylation motif of p38-MAPKα indicated that it can be
enzymically-activated [to (pT-G-F)p38-MAPKα, etc.] by its MAPK
kinase in vitro, but its activity is only ~5% that of (pT-G-pY)p38-
MAPKα [35]. In vivo, constitutively-active MKK6 transfected into
HEK293T cells activated transfected (T-G-F)p38-MAPKα, but this did
not lead to activation of an AP-1-luciferase reporter above that seen in
cells transfected with constitutively-active MKK6 alone [35]. Largely-
analogous results were obtained with mutants of the yeast p38-
MAPKα orthologue HOG-1 where phosphorylation of Thr-, but not
Tyr-, was essential for both catalytic and biological activity [36].
Our data do not conﬂict with the accepted ordered phosphoryla-
tion mechanism. The appearance of (pT-E-Y)ERK1/2 is delayed
relative to (pT-E-pY)ERK1/2 (Fig. 3), consistent with obligate initial
phosphorylation of the Tyr- residue. As suggested [10], it seems likely
that (pT-E-Y)ERK1/2 are generated through dephosphorylation of
(pT-E-pY)ERK1/2 by one or more PTPs. On the assumption that a
'classical' Cys-dependent PTP dephosphorylates (pT-E-pY)ERK1/2,
~15 candidates have been identiﬁed as being expressed in cardiac
myocytes by our transcriptomics data (A. Clerk, unpublished data). A
ﬁnal question relates to the potential role of (pT-E-Y)ERK1/2 in vivo.
The biological role(s) of (pT-E-Y)ERK1/2 is unclear. Given that pY-185
in ERK2 forms part of the substrate recognition pocket, (pT-E-Y)ERK1/
2 may differ from (pT-E-pY)ERK1/2 in terms of substrate speciﬁcity.Acknowledgements
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